-
Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts
Monday, June 5, 2017 - 3:54pm | 1228Read More...If investors were to sum up the year 2017 for specialty drug maker RedHill Biopharma Ltd - ADR (NASDAQ: RDHL) in one phrase, it might be this: “catalyst-rich.” A specialty biopharmaceutical company based in Israel, RedHill has a treasure trove of developing drugs in its pipeline to...
-
Protagonist Therapeutics Spikes Sharply After Agreement With Janssen
Tuesday, May 30, 2017 - 11:12am | 168Read More...Protagonist Therapeutics Inc(NASDAQ: PTGX) shares are trading higher by $3.54 — over 43 percent — at $11.76 in Tuesday's session. Investors are aggressively purchasing shares of the company following the announcement that the company has entered a agreement with Janssen to co-develop...
-
Celgene Shares Higher On Positive Crohn's Patient Data
Monday, October 17, 2016 - 3:33pm | 358Read More...Celgene Corporation (NASDAQ: CELG) shares are up a modest 1.2 percent in Mondays session after the company’s United European Gastroenterology Week (UEGW) abstract revealed wide-spread activity for mongersen (GED-301) among Crohn’s patients. Although the full data will not be available...
-
AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management
Tuesday, May 24, 2016 - 12:14pm | 379Read More...AbbVie Inc (NYSE: ABBV) disclosed that it presented a proof of concept, Phase II trial in Crohn's disease with investigatory biologic risankizumab, a compound from Boehringer Ingelheim research and recently licensed by the company. According to the company, Risankizumab was shown to be more...
-
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade
Wednesday, April 6, 2016 - 10:45am | 327Read More...Pfizer Inc. (NYSE: PFE) announced after Tuesday's market close that the U.S. Food and Drug Administration approved INFLECTRA, the first and only biosimilar monoclonal antibody therapy, and only the second biosimilar to be approved in the US. INFLECTRA is a treatment indicated for reducing...
